Parkinson’s Disease

Parkinson's disease is a progressive neurodegenerative disorder, first described in 1817 by Dr. James Parkinson. The prevalence is estimated at 0.3% of the whole population in industrialized countries, rising to 1% in those over 60 years of age and to 4% of the population over 80. It is one of the most common neurologic disorders of the elderly.

Test Results


The BBB(Blood-Brain-Barrier) is a highly selective semipermeable membrance barrier that separates the circulating blood from the brain and extracellular fluid in the central nervous system. Several studies have been conducted to find ways to penetrate through the barrier for brain diseases treatment and for contrast medium development.

BBB Aptamer

Today’s treatments for degenerative brain diseases face difficulty having molecules penetrate through the Blood Brain Barrier (BBB). Many pharmaceutical companies are conducting studies using antibodies to increase brain permeability of the drugs, but the shortcomings and side effects of the antibodies still need to be resolved. We have been developing BBB Aptamers penetrating through the blood-brain barrier.

Theragnosis(Therapy + Diagnosis)

As recent studies have proven that aptamers bound with alpha-synuclein help prevent proteins from generating oligomers, the hypothesis that aptamers can be used as BBB treatments has been proved alongside. We are currently developing CNS Aptamer Treatments for Parkinson’s Disease and Alzheimer’s Disease. With the development of CNS Aptamer treatment, we are also researching CNS Aptamer applied to contrast media. By successful development of BBB aptamer applied on CNS Aptamer, we expect to diagnose and cure the diseases at the same time in the near future.

Immune Clearance

Immune Clearance is a method that binds inflammatory factors with antibodies and eliminates them with phagocytosis in microglia. We are developing BBB aptamers combined with such methodology. Substituting antibodies that cannot pass through the blood-brain barrier, BBB aptamers will be able to capture target proteins such as alpha-synuclein or amyloid beta. The captured targets will in turn be eliminated by microglia, providing a new solution to cure diseases.